Evidence map›Paper›PMID 39286032›Full record

ArticleOpen forum infectious diseases2024

Effectiveness of the Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters in Pregnant Persons Who Were Not Immunocompromised: VISION Network, June 2022-August 2023.

Allison Avrich Ciesla, Victoria Lazariu, Kristin Dascomb, Stephanie A Irving, Brian E Dixon, Manjusha Gaglani, Allison L Naleway, Shaun J Grannis, Sarah Ball, Anupam B Kharbanda and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Allison Avrich CieslaCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-8739-1005
Victoria LazariuWestat, Rockville, Maryland, USA.
Kristin DascombDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Health, Salt Lake City, Utah, USA.
Stephanie A IrvingKaiser Permanente Center for Health Research, Portland, Oregon, USA.
Brian E DixonCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
Manjusha GaglaniSection of Pediatric Infectious Diseases, Department of Pediatrics, Baylor Scott & White Health, Temple, Texas, USA.ORCID https://orcid.org/0000-0002-3952-9230
Allison L NalewayKaiser Permanente Center for Health Research, Portland, Oregon, USA.
Shaun J GrannisCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, Indiana, USA.
Sarah BallWestat, Rockville, Maryland, USA.
Anupam B KharbandaChildren's Minnesota, Minneapolis, Minnesota, USA.
Gabriela Vazquez-BenitezHealthPartners Institute, Minneapolis, Minnesota, USA.
Nicola P KleinKaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, USA.ORCID https://orcid.org/0000-0003-1777-4814
Karthik NatarajanDepartment of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.
Toan C OngSchool of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Peter J EmbiVanderbilt University Medical Center, Nashville, Tennessee, USA.
Katherine E Fleming-DutraCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ruth Link-GellesCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-9617-806X
Ousseny ZerboKaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, California, USA.ORCID https://orcid.org/0000-0002-8380-6215

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pregnant people face increased risk of severe COVID-19. Current guidelines recommend updated COVID-19 vaccination (2023-2024) for those aged ≥6 months, irrespective of pregnancy status. To refine recommendations for pregnant people, further data are needed. Using a test-negative design, we evaluated COVID-19 vaccine effectiveness against medically attended COVID-19 with COVID-19-like illness among pregnant people aged 18 to 45 years during June 2022 to August 2023. When doses were received during pregnancy, vaccine effectiveness was 52% (95% CI, 29%-67%); when received <6 months prior to pregnancy, 28% (95% CI, 11%-42%); and when received ≥6 months prior to pregnancy, 6% (95% CI, -11% to 21%). Pregnant people should stay up-to-date with recommended COVID-19 vaccination.

Indexed as

COVID-19pregnant personspublic healthSARS-CoV-2vaccine effectiveness

Identifiers

PMID39286032
PMCPMC11403472

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.